A study was conducted to examine sex differences in subjective symptoms of fatigue in men and women with reference to the experience of awareness and cognitive appraisal based on symptom of fatigue content. A total of 54 questionnaire items were administered to 730 people (290 men and 440 women) . The subjects indicated whether or not they were aware of the content, and to what degree the content of the question for each item was important. Sex differences in the response to the ratio of awareness and the degree of importance were then. The mean importance scores for subjective symptoms of fatigue in men and women were 3.9-5.4 and 4.5-5.6, respectively. It was found that a majority of the men and women showed awareness of each item. A significant difference was recognized in the factor of awareness in all items as a result of two-way ANOVA of the degree of importance by which the presence of awareness and its sex difference were assumed to be factors, and those who were aware deemed the degree of importance high. On the other hand, the 28 items for which a significant sex difference was recognized showed a high value, and there was a marked content of Languor, Loss of Vigor, and A Feeling of Impatience and Physical Disintegration in women. In the same items, it was inferred that persons who were more aware than the persons who were not aware regarded subjective symptoms of fatigue as important. Most items in which a main effect of sex was recognized were content of Loss of Vigor and a Feeling of Impatience and Physical Disintegration. It was thought that women considered these symptoms more important than men. The sex difference in symptoms of fatigue was inferred to be due to the difference in the level of acknowledgment based on experienced knowledge.

The purpose of this study was to verify the concept of Kampo medicine epidemiologically and demonstrate the objective bases of the Kampo treatment. For this purpose, a population based survey of subjective symptoms based on Kampo medicine was conducted among 1,486 residents of Hase village, Nagano prefecture, ages 20 and older. The completion rate was 80.7% and 1,199 residents provided favorable responses. An investigation of gender differences showed a higher rate of blood deficiency among female residents, while spleen and qi deficiency were more common in males. Considering age differences, symptoms related to blood deficiency and water-dampness affected younger females, symptoms related to qi deficiency primarily affected younger males, and symptoms of liver afflictions were common in younger both genders. Among the elderly residents, symptoms of kidney deficiency were overwhelmingly predominant in both genders. Though younger people with subjective sense of health had few diseases in western medicine, most of the elderly with perceived health actually had some kind of diseases for medical treatment. Physical symptoms in the chest area such as shortness of breath correlated positively with the perception not to be healthy, and these may be regarded as both the manifestation and factors contributing to ill health. Approximately 1 out of 12 residents reported currently receiving the treatment of oriental medicine or demonstrated the potential to benefit from such intervention. These results may clinically be useful as the objective bases to perform the Kampo treatment.

OBJECTIVE: The aim of the present study was to perform a subgroup analysis of data from a phase II global, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of bitopertin, a glycine reuptake inhibitor that activates N-methyl-D-aspartate receptors by increasing the concentration of glycine in the synaptic cleft, in Japanese and non-Japanese patients with schizophrenia and predominant negative symptoms. METHODS: Patients with schizophrenia and predominant negative symptoms on one or two antipsychotic drugs, including atypical antipsychotic drugs (olanzapine, risperidone, quetiapine, aripiprazole, and paliperidone) as the primary treatment, received bitopertin (10, 30, or 60 mg/day) or placebo once daily for 8 weeks as an add-on treatment. Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) negative symptom factor score (NSFS). RESULTS: The efficacy of bitopertin (10 mg and 30 mg) was similar between Japanese and non-Japanese patients. In the bitopertin 60-mg group, no difference from the placebo group was observed in Japanese or non-Japanese patients. The response to placebo was lower in Japanese patients, and there was a trend towards a greater difference in the change in PANSS NSFS between the placebo group and the 10-mg and 30-mg groups among Japanese patients. The safety profile of bitopertin was favorable in Japanese and non-Japanese patients. CONCLUSION: According to this subgroup analysis from a global phase II study of bitopertin, there was no difference in terms of efficacy and safety between Japanese and non-Japanese patients.
Antipsychotic Agents ; Aripiprazole ; Asian Continental Ancestry Group* ; Glycine ; Humans ; Japan ; Quetiapine Fumarate ; Receptors, N-Methyl-D-Aspartate ; Risperidone ; Schizophrenia*